Nasal Polyps Keep Coming Back. Your Genes May Be Why.

Your HLA genes are the gatekeepers of immune recognition. They sit on the surface of immune cells and present fragments of proteins to the T-cell army, essentially showing them what to attack. HLA-DQ2 is one of the most common and influential of these presenters. It determines how readily your immune system recognizes and responds to allergens and other substances.

The HLA-DQ2 variant, carried by roughly 25-30% of people with European ancestry, isn’t a simple on-off switch. It’s a recognition template that makes your immune system exceptionally good at spotting certain allergens. People with HLA-DQ2 tend to mount faster, stronger Th2 immune responses to inhaled allergens, priming the ground for polyp formation.

This is why some people with nasal allergies develop polyps while others don’t. Your HLA-DQ2 status determines whether your immune system treats a simple dust or pollen exposure as a minor irritant or a full-blown threat requiring inflammation and tissue remodeling.

Interleukin-13 is a signaling molecule released by Th2 immune cells. Its job in healthy amounts is to manage parasites and wound healing. But when it’s overproduced, it becomes the primary driver of everything that makes polyps grow: airway eosinophilia (buildup of immune cells), mucus hypersecretion, and airway tissue remodeling.

The IL13 variants, found in roughly 30-35% of the population, amplify this process. Carriers with IL13 variants produce more IL-13 when exposed to allergens, which directly signals nasal tissue to swell, produce excess mucus, and remodel into polyp-like growths.

This is why IL13-positive people often describe polyps that feel softer and more mucus-laden compared to other types. The inflammation drives tissue proliferation at a faster rate. Without addressing IL13 overproduction, steroid sprays alone often fall short.

Interleukin-4 is the primary signaling molecule that tells your immune system to tilt toward Th2 responses, the allergic and inflammatory pathway. It stimulates B cells to produce IgE (the antibody behind allergies) and drives the overall Th2 phenotype. In proper balance, it’s essential. But when overproduced, it creates a system primed for hyperresponsiveness to allergens.

The IL4 -590C>T variant, present in roughly 30% of the population, increases IL-4 production, particularly in response to allergen exposure. This variant strongly predisposes carriers to Th2-skewed immunity, higher IgE production, and greater susceptibility to allergic rhinitis and nasal polyps.

IL4 carriers often report that their allergies seem disproportionate to the allergen exposure. A few particles of pollen trigger an outsized inflammatory response. This genetic bias toward Th2 immunity is fundamental to polyp formation.

Filaggrin is a structural protein that holds together the tight junctions in your skin and airway barriers. It’s the mortar between the bricks. When your FLG gene works properly, it creates a continuous, impermeable barrier that prevents allergens from crossing into the deeper tissues where immune cells wait.

The FLG variants R501X and 2282del4, carried by roughly 10% of people with European ancestry, disrupt filaggrin production and assembly. This barrier dysfunction allows allergens to penetrate directly into the lamina propria, where they trigger immediate Th2 immune activation and chronic inflammation.

FLG carriers often have a history of eczema alongside their nasal polyps, part of what’s called the atopic march. Once allergens breach the barrier, they encounter your immune system directly, and if you also carry IL4, IL13, or HLA-DQ2 variants, the response is severe.

Toll-like receptor 4 sits on the surface of immune cells and recognizes lipopolysaccharide (LPS), a component of gram-negative bacteria. Its job is to alert your immune system to bacterial presence. When TLR4 works properly, it triggers a rapid, proportionate immune response. When it doesn’t, recognition is delayed or dampened.

The TLR4 D299G variant, found in roughly 10% of people with European ancestry, reduces LPS recognition capability. Carriers have impaired early bacterial immune responses, which can allow secondary bacterial colonization and biofilm formation in the sinus polyp tissue itself.

This is often why TLR4 carriers with polyps report recurrent sinus infections. The polyps form from allergic inflammation, but then bacteria colonize the polyp tissue more easily because your innate immune system doesn’t sense and fight them as quickly. You end up with chronic sinus infections layered on top of chronic inflammation.

The vitamin D receptor is a nuclear receptor that binds activated vitamin D and regulates the expression of hundreds of immune genes. Vitamin D is not just a bone nutrient; it’s a powerful immune regulator that shifts immunity away from Th2 and toward more balanced responses. Without a properly functioning VDR, even adequate vitamin D levels don’t translate into immune regulation.

VDR variants such as FokI (rs2228570), BsmI (rs1544410), and ApaI (rs7975232), which are common across all populations, reduce VDR function and vitamin D signaling capacity. Carriers have reduced vitamin D-driven immune regulation, allowing Th2 skewing and chronic airway inflammation to proceed unchecked.

VDR carriers often discover they have low-normal or frankly low vitamin D levels when tested. But even when supplemented, their immune system remains Th2-biased because the receptor itself isn’t translating the vitamin D signal properly into immune dampening.